IntraClude Intra-Aortic Occlusion Device, REF: ICF100, 10.5 Fr (3.5 mm) X 39.4" (100 cm), Rx Only, Sterile EO The IntraClude intra-aortic occlusion device is indicated for use in patients undergoing cardiopulmonary bypass. The IntraClude intra-aortic occlusion device occludes and vents the ascending aorta when the balloon is inflated.
Publicado el 19 de junio de 2019 · Inicio del retiro: 14 de mayo de 2019
Resumen
FDA registra el retiro Z-1705-2019 de dispositivos médicos de Clase I, publicado el 19 de junio de 2019 e iniciado el 14 de mayo de 2019. Empresa responsable: Edwards Lifesciences, LLC; Estado: Finalizado; Cantidad reportada: 6552; Lote: All lot numbers. La Clase I indica una probabilidad razonable de consecuencias graves para la salud o muerte.
Estado reportado al momento de publicación: Terminated — openFDA actualiza semanalmente y este campo no refleja el estado más reciente. Confirma siempre con la fuente oficial.
Qué peligro representa
Possibility of balloon rupture in intra-aortic occlusion devices. If the balloon bursts during cardiopulmonary bypass, the heart can fill and warm, the operative site may be obscured, and the device will need to be exchanged or operative strategy would need to change, including placement of an external cross-clamp, conversion to an open procedure, or performing the procedure under fibrillation.
Qué hacer
Voluntary: Firm initiated · Letter
Recibe un correo cuando FDA publique un retiro como este
Gratis. Solo te escribimos cuando hay un retiro nuevo que coincide. Te das de baja con un clic.
Detalles del retiro
- Fabricante
- Edwards Lifesciences, LLC
- Distribuidor
- Worldwide Distribution: US (nationwide) to states of: UT, GA, NJ, CA, OH, PA, AL, FL, TN, TX, ME, MA, IN, MS, NY, VA, MI, IL, CO, OR, WA, SC, AZ, SD, MO, CT, OK, NV, WV, WI, NC, MN, KY; and countries of: United Arab Emirates, Austria, Australia, Belgium, Canada, Switzerland, Colombia, Czech Republic, Germany, France, United Kingdom, Italy, Netherlands, Poland, Romania, and Sweden.
- Lote
- All lot numbers.
- Clasificación de riesgo
- Class I
- Área (FDA)
- device
- País
- United States
Retiros relacionados
- FDAGeneric Name: Edwards Commander M Delivery System Generic Name: Edwards Commander M Delivery System11 de noviembre de 2026
- FDAEdwards EVOQUE tricuspid delivery system REF:9850TDS Sterile EO20 de mayo de 2026
- FDABrand Name: FEM-FLEX II Product Name: Femoral Arterial Cannula Model/Catalog Number: FEMII016AS Software16 de julio de 2025
- FDABrand Name: Optisite Arterial Cannula Product Name: Optisite Arterial Cannula Model/Catalog Number: OPTI1616 de julio de 2025
- FDAPerformance Mushrooms product is dried mushroom blend of 4 different mushroom mycelial biomass powders19 de junio de 2019
- FDAPrestige II, Prestige SI, Prestige VH Prestige system is a new multi-purpose conventional and digital R/F19 de junio de 2019
Preguntas sobre este retiro
¿IntraClude Intra-Aortic Occlusion Device, REF: ICF100, 10.5 Fr (3.5 mm) X 39.4" (100 cm), Rx Only, Sterile EO The IntraClude intra-aortic occlusion device is indicated for use in patients undergoing cardiopulmonary bypass. The IntraClude intra-aortic occlusion device occludes and vents the ascending aorta when the balloon is inflated. fue retirado del mercado?
Sí. FDA publicó el retiro Z-1705-2019 el 19 de junio de 2019. Peligro reportado: Possibility of balloon rupture in intra-aortic occlusion devices. If the balloon bursts during cardiopulmonary bypass, the heart can fill and warm, the operative site may be obscured, and the device will need to be exchanged or operative strategy would need to change, including placement of an external cross-clamp, conversion to an open procedure, or performing the procedure under fibrillation.
¿Qué debo hacer si tengo este producto?
Voluntary: Firm initiated · Letter